These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 19270263)

  • 21. Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.
    Carcas AJ; Borobia AM; Velasco M; Abad-Santos F; Díaz MQ; Fernández-Capitán C; Ruiz-Giménez N; Madridano O; Sillero PL;
    Trials; 2012 Dec; 13():239. PubMed ID: 23237631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle.
    Pérez-Andreu V; Teruel R; Corral J; Roldán V; García-Barberá N; Salloum-Asfar S; Gómez-Lechón MJ; Bourgeois S; Deloukas P; Wadelius M; Vicente V; González-Conejero R; Martínez C
    Mol Med; 2013 Jan; 18(1):1466-72. PubMed ID: 23154637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.
    Danese E; Montagnana M; Johnson JA; Rettie AE; Zambon CF; Lubitz SA; Suarez-Kurtz G; Cavallari LH; Zhao L; Huang M; Nakamura Y; Mushiroda T; Kringen MK; Borgiani P; Ciccacci C; Au NT; Langaee T; Siguret V; Loriot MA; Sagreiya H; Altman RB; Shahin MH; Scott SA; Khalifa SI; Chowbay B; Suriapranata IM; Teichert M; Stricker BH; Taljaard M; Botton MR; Zhang JE; Pirmohamed M; Zhang X; Carlquist JF; Horne BD; Lee MT; Pengo V; Guidi GC; Minuz P; Fava C
    Clin Pharmacol Ther; 2012 Dec; 92(6):746-56. PubMed ID: 23132553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.
    Borobia AM; Lubomirov R; Ramírez E; Lorenzo A; Campos A; Muñoz-Romo R; Fernández-Capitán C; Frías J; Carcas AJ
    PLoS One; 2012; 7(7):e41360. PubMed ID: 22911785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians.
    Rathore SS; Agarwal SK; Pande S; Singh SK; Mittal T; Mittal B
    PLoS One; 2012; 7(5):e37844. PubMed ID: 22629463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.
    Moreau C; Bajolle F; Siguret V; Lasne D; Golmard JL; Elie C; Beaune P; Cheurfi R; Bonnet D; Loriot MA
    Blood; 2012 Jan; 119(3):861-7. PubMed ID: 22130800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.
    Lacut K; Ayme-Dietrich E; Gourhant L; Poulhazan E; Andro M; Becquemont L; Mottier D; Le Gal G; Verstuyft C
    Br J Clin Pharmacol; 2012 Mar; 73(3):428-36. PubMed ID: 21883387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic background of patients from a university medical center in Manhattan: implications for personalized medicine.
    Tayo BO; Teil M; Tong L; Qin H; Khitrov G; Zhang W; Song Q; Gottesman O; Zhu X; Pereira AC; Cooper RS; Bottinger EP
    PLoS One; 2011 May; 6(5):e19166. PubMed ID: 21573225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
    Shahin MH; Khalifa SI; Gong Y; Hammad LN; Sallam MT; El Shafey M; Ali SS; Mohamed ME; Langaee T; Johnson JA
    Pharmacogenet Genomics; 2011 Mar; 21(3):130-5. PubMed ID: 21228733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway.
    Hsu MH; Savas U; Lasker JM; Johnson EF
    J Pharmacol Exp Ther; 2011 Apr; 337(1):125-36. PubMed ID: 21205922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
    Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
    Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.
    Puehringer H; Loreth RM; Klose G; Schreyer B; Krugluger W; Schneider B; Oberkanins C
    Eur J Clin Pharmacol; 2010 Jun; 66(6):591-8. PubMed ID: 20376629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
    Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
    Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
    Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
    Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.
    Pérez-Andreu V; Roldán V; Antón AI; García-Barberá N; Corral J; Vicente V; González-Conejero R
    Blood; 2009 May; 113(20):4977-9. PubMed ID: 19270263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.
    Pérez-Andreu V; Roldán V; López-Fernández MF; Antón AI; Alberca I; Corral J; Montes R; García-Barberá N; Ferrando F; Vicente V; González-Conejero R
    J Thromb Haemost; 2010 May; 8(5):1012-7. PubMed ID: 20149073
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.